0001104659-23-120363.txt : 20231121 0001104659-23-120363.hdr.sgml : 20231121 20231121161525 ACCESSION NUMBER: 0001104659-23-120363 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20231120 ITEM INFORMATION: Other Events FILED AS OF DATE: 20231121 DATE AS OF CHANGE: 20231121 FILER: COMPANY DATA: COMPANY CONFORMED NAME: STANDARD BIOTOOLS INC. CENTRAL INDEX KEY: 0001162194 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 770513190 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-34180 FILM NUMBER: 231428297 BUSINESS ADDRESS: STREET 1: 2 TOWER PLACE STREET 2: SUITE 2000 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 6502666000 MAIL ADDRESS: STREET 1: 2 TOWER PLACE STREET 2: SUITE 2000 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: FLUIDIGM CORP DATE OF NAME CHANGE: 20011113 8-K 1 tm2331299d1_8k.htm FORM 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 20, 2023

Standard BioTools Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-34180

77-0513190

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

2 Tower Place, Suite 2000

South San Francisco, California

94080

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s telephone number, including area code: (650) 266-6000

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

x	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, par value $0.001 per share	LAB	Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 8.01

Other Events.

As previously disclosed, on October 4, 2023, Standard BioTools Inc., a Delaware corporation (“Standard BioTools” or the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) by and among the Company, SomaLogic, Inc., a Delaware corporation (“SomaLogic”), and Martis Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“Merger Sub”), pursuant to which, among other matters, Merger Sub will merge with and into SomaLogic (the “Merger”), with SomaLogic surviving the Merger as a wholly owned subsidiary of the Company.

The completion of the Merger is conditioned upon, among other things, the expiration of any waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), applicable to the consummation of the Merger (the “HSR Waiting Period”). The HSR Waiting Period expired at 11:59 p.m., Eastern Time, on November 20, 2023.

The completion of the Merger remains subject to the satisfaction of other closing conditions as previously disclosed and specified in the Merger Agreement. Standard BioTools continues to expect to complete the Merger in the first quarter of 2024.

Additional Information and Where to Find It

In connection with the Merger and required stockholder approval, Standard BioTools filed with the U.S. Securities and Exchange Commission (the “SEC”) a registration statement on Form S-4, dated November 13, 2023 (the “Form S-4”), that includes a preliminary joint proxy statement of Standard BioTools and SomaLogic that also constitutes a preliminary prospectus of Standard BioTools. Each of Standard BioTools and SomaLogic also plan to file other relevant documents with the SEC regarding the Merger. Any definitive joint proxy statement/prospectus (if and when available) will be mailed to stockholders of Standard BioTools and SomaLogic. Standard BioTools’ and SomaLogic’s stockholders are urged to carefully read the joint proxy statement/prospectus (including all amendments, supplements and any documents incorporated by reference therein) and other relevant materials filed or to be filed with the SEC and in their entirety when they become available because they will contain important information about the Merger and the parties to the Merger. Investors and stockholders may obtain free copies of these documents (when they are available) and other documents filed with the SEC at its website at http://www.sec.gov. In addition, investors may obtain free copies of the documents filed with the SEC by Standard BioTools by going to Standard BioTools’ Investor Relations website at http://investors.standardbio.com or contacting Standard BioTools’ Investor Relations department at investors@standardbio.com or by SomaLogic by going to SomaLogic’s Investor Relations page on its corporate website at https://investors.somalogic.com or by contacting SomaLogic Investor Relations at investors@somalogic.com.

Participants in the Solicitation

Standard BioTools, SomaLogic and each of their respective executive officers and directors may be deemed to be participants in the solicitation of proxies from Standard BioTools’ stockholders with respect to the Merger. Information about Standard BioTools’ directors and executive officers, including their ownership of Standard BioTools’ securities, is set forth in the Form S-4, which was filed with the SEC on November 13, 2023, Standard BioTools’ proxy statement for its 2023 Annual Meeting of Stockholders, which was filed with the SEC on April 28, 2023, Current Reports on Form 8-K, which were filed with the SEC on May 3, 2023, May 15, 2023, June 16, 2023 and July 28, 2023, and Standard BioTools’ other filings with the SEC. Information concerning SomaLogic’s directors and executive officers, including their ownership of SomaLogic securities, is set forth in the Form S-4, which was filed with the SEC on November 13, 2023, SomaLogic’s proxy statement for its 2023 Annual Meeting of Stockholders, which was filed with the SEC on April 25, 2023, Current Reports on Form 8-K, which were filed with the SEC on June 6, 2023, as amended on June 14, 2023, June 9, 2023 and October 4, 2023, and SomaLogic’s other filings with the SEC. Investors may obtain more detailed information regarding the direct and indirect interests of Standard BioTools and its respective executive officers and directors in the Merger, which may be different than those of Standard BioTools’ stockholders generally, by reading the preliminary and definitive proxy statements regarding the Merger, which have been or will be filed with the SEC. These documents are available free of charge at the SEC’s website at www.sec.gov, by going to Standard BioTools’ Investor Relations website at http://investors.standardbio.com or by contacting Standard BioTools’ Investor Relations department at investors@standardbio.com or by going to SomaLogic’s Investor Relations page on its corporate website at https://investors.somalogic.com or by contacting SomaLogic Investor Relations at investors@somalogic.com.

No Offer or Solicitation

This Current Report on Form 8-K and the information contained herein shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

Forward-Looking Statements

This Current Report on Form 8-K contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based upon current plans, estimates and expectations of the management of Standard BioTools and SomaLogic that are subject to various risks and uncertainties that could cause actual results to differ materially from such statements, many of which are beyond the control of Standard BioTools and SomaLogic. All statements other than statements of historical fact (including statements containing the words “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) are statements that could be deemed forward-looking statements, although not all forward-looking statements contain these identifying words. Readers should not place undue reliance on these forward-looking statements. Forward-looking statements may include statements regarding the expected timing of the closing of the Merger; the ability of the parties to complete the Merger considering the various closing conditions; and any assumptions underlying any of the foregoing. Statements regarding future events are based on the parties’ current expectations and are necessarily subject to associated risks related to, among other things, (i) the risk that the Merger may not be completed in a timely manner or at all, which may adversely affect Standard BioTools’ and SomaLogic’s businesses and the price of their respective securities; (ii) uncertainties as to the timing of the consummation of the Merger and the potential failure to satisfy the conditions to the consummation of the Merger, including obtaining stockholder and regulatory approvals; (iii) the Merger may involve unexpected costs, liabilities or delays; (iv) the effect of the announcement, pendency or completion of the Merger on the ability of Standard BioTools or SomaLogic to retain and hire key personnel and maintain relationships with customers, suppliers and others with whom Standard BioTools or SomaLogic does business, or on Standard BioTools’ or SomaLogic’s operating results and business generally; (v) Standard BioTools’ or SomaLogic’s respective businesses may suffer as a result of uncertainty surrounding the Merger and disruption of management’s attention due to the Merger; (vi) the outcome of any legal proceedings related to the Merger or otherwise, or the impact of the Merger thereupon; (vii) Standard BioTools or SomaLogic may be adversely affected by other economic, business and/or competitive factors, (viii) the occurrence of any event, change or other circumstances that could give rise to the termination of the Merger agreement and the Merger; (ix) restrictions during the pendency of the Merger that may impact Standard BioTools’ or SomaLogic’s ability to pursue certain business opportunities or strategic transactions; (x) the risk that Standard BioTools or SomaLogic may be unable to obtain governmental and regulatory approvals required for the Merger, or that required governmental and regulatory approvals may delay the consummation of the Merger or result in the imposition of conditions that could reduce the anticipated benefits from the Merger or cause the parties to abandon the Merger; (xi) risks that the anticipated benefits of the Merger or other commercial opportunities may otherwise not be fully realized or may take longer to realize than expected; (xii) the impact of legislative, regulatory, economic, competitive and technological changes; (xiii) risks relating to the value of the Standard BioTools shares to be issued in the Merger; (xiv) the risk that post-closing integration of the Merger may not occur as anticipated or the combined company may not be able to achieve the benefits expected from the Merger, as well as the risk of potential delays, challenges and expenses associated with integrating the combined company’s existing businesses; (xv) exposure to inflation, currency rate and interest rate fluctuations, as well as fluctuations in the market price of Standard BioTools’ and SomaLogic’s traded securities; (xvi) the lingering effects of the COVID-19 pandemic on Standard BioTools’ and SomaLogic’s industry and individual companies, including on counterparties, the supply chain, the execution of research and development programs, access to financing and the allocation of government resources; (xvii) the ability of Standard BioTools or SomaLogic to protect and enforce intellectual property rights; and (xviii) the unpredictability and severity of catastrophic events, including, but not limited to, acts of terrorism or outbreak of war or hostilities, as well as Standard BioTools’ and SomaLogic’s response to any of the aforementioned factors. Therefore, actual results may differ materially and adversely from those expressed in any forward-looking statements. For information regarding other related risks, see the “Risk Factors” section of Standard BioTools’ most recent quarterly report on Form 10-Q filed with the SEC on November 7, 2023, on its most recent annual report on Form 10-K filed with the SEC on March 14, 2023 and in Standard BioTools’ other filings with the SEC, as well as the “Risk Factors” section of SomaLogic’s most recent quarterly report on Form 10-Q filed with the SEC on November 8, 2023, on its most recent annual report on Form 10-K filed with the SEC on March 28, 2023 and in SomaLogic’s other filings with the SEC. The risks and uncertainties described above and in the SEC filings cited above are not exclusive and further information concerning Standard BioTools and SomaLogic and their respective businesses, including factors that potentially could materially affect their respective businesses, financial conditions or operating results, may emerge from time to time. Readers are urged to consider these factors carefully in evaluating these forward-looking statements, and not to place undue reliance on any forward-looking statements. Any such forward-looking statements represent management’s reasonable estimates and beliefs as of the date of this Current Report on Form 8-K. While Standard BioTools and SomaLogic may elect to update such forward-looking statements at some point in the future, they disclaim any obligation to do so, other than as may be required by law, even if subsequent events cause their views to change.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 21, 2023	STANDARD BIOTOOLS INC.

	By:	/s/ Jeffrey Black
	Name:	Jeffrey Black
	Title:	Chief Financial Officer

EX-101.SCH 2 lab-20231120.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 lab-20231120_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 4 lab-20231120_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 5 R1.htm IDEA: XBRL DOCUMENT

Cover	Nov. 20, 2023
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Nov. 20, 2023
Entity File Number	001-34180
Entity Registrant Name	Standard BioTools Inc.
Entity Central Index Key	0001162194
Entity Tax Identification Number	77-0513190
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	2 Tower Place
Entity Address, Address Line Two	Suite 2000
Entity Address, City or Town	South San Francisco
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94080
City Area Code	650
Local Phone Number	266-6000
Written Communications	true
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common stock, par value $0.001 per share
Trading Symbol	LAB
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false

XML 6 tm2331299d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001162194 2023-11-20 2023-11-20 iso4217:USD shares iso4217:USD shares false 0001162194 8-K 2023-11-20 Standard BioTools Inc. DE 001-34180 77-0513190 2 Tower Place Suite 2000 South San Francisco CA 94080 650 266-6000 true false false false Common stock, par value $0.001 per share LAB NASDAQ false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://standardbio/role/Cover Cover Cover 1 false false All Reports Book All Reports lab-20231120.xsd lab-20231120_lab.xml lab-20231120_pre.xml tm2331299d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm2331299d1_8k.htm": { "nsprefix": "LAB", "nsuri": "http://standardbio/20231120", "dts": { "schema": { "local": [ "lab-20231120.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "lab-20231120_lab.xml" ] }, "presentationLink": { "local": [ "lab-20231120_pre.xml" ] }, "inline": { "local": [ "tm2331299d1_8k.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://standardbio/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-11-20", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2331299d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-11-20", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2331299d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 13 0001104659-23-120363-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-120363-xbrl.zip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end